MERECA Study Reveals Survival Benefits for Metastatic Synchronous mRCC with Combo of Ilixadencel plus Sutent

The combination of ilixadencel plus sunitinib (Sutent) has evidenced favorable survival compared with sunitinib alone in patient with newly diagnosed metastatic synchronous renal cell carcinoma (mRCC), clinical sponsor Immunicum AB recently announced and will present...

Pin It on Pinterest